ArticleScientific reports2024
Predicting prognosis in colorectal cancer patients with curative resection using albumin, lymphocyte count and RAS mutations.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: A secondary analysis of the CANVAS trial.Thrombosis research · 2024Trial
- Integrating the lymphocyte-albumin score into prognostic stratification of nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy.Frontiers in physiology · 2026Article
- Immunologically-based nutritional status assessment amongst preoperative colorectal cancer patients - does it link to TNM stage.Frontiers in immunology · 2026Article
- Preoperative albumin to carcinoembryonic antigen ratio predicts clinicopathological features and survival in colorectal cancer: a prognostic nomogram study.Frontiers in oncology · 2026Article
- Coordinated dynamics of circulating neutrophils, regulatory T lymphocytes, myeloid derived suppressor cells and distinct granulocytic subsets reveal a complex immune network in metastatic colorectal cancer.Frontiers in oncology · 2026Article
- Impact of PG-SGA-assessed malnutrition stratification on clinical outcomes in advanced gastrointestinal malignancies: a retrospective cohort study.BMC gastroenterology · 2025Article
- Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Oral microbiota signature predicts the prognosis of colorectal carcinoma.NPJ biofilms and microbiomes · 2025Article
- Improving postoperative outcomes in patients with pancreatic cancer: Inflammatory and nutritional biomarkers.World journal of clinical oncology · 2025Article
- High systemic inflammation response index (SIRI) level as a prognostic factor for colorectal cancer patients after curative surgery: a single-center retrospective analysis.Scientific reports · 2025Article
- Diagnostic accuracy evaluation of individual or combinational fecal immunochemical test, M3 gene, KRAS mutation and tumor methylation burden in colorectal carcinoma.Frontiers in immunology · 2025Article
- Establishment and Validation of a Novel Nutritional-Immune-Inflammatory Score Model for Predicting Survival Prognosis in Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Colorectal cancer (CRC) poses a significant global health challenge, demanding reliable prognostic tools to guide treatment decisions. This study introduces a novel prognostic scoring system, the albumin-total lymphocyte count-RAS index (ALRI), integrating serum albumin, lymphocyte count, and RAS gene mutations. A cohort of 445 stage I-III CRC patients undergoing curative resection was analyzed, revealing ALRI's association with clinicopathological factors, including age, tumor location, and invasion depth. The ALRI demonstrated superior prognostic value, with a cutoff value of 2 distinguishing high and low-risk groups. The high-ALRI group exhibited elevated rates of recurrence. Univariate and multivariate analyses identified ALRI as an independent predictor for both 5 year recurrence-free survival (RFS) and overall survival (OS). Kaplan-Meier curves illustrated significant differences in RFS and OS between high and low-ALRI groups, emphasizing ALRI's potential as a prognostic marker. Importantly, ALRI outperformed existing nutritional indices, such as controlling nutritional status and neutrophil-to-lymphocyte ratio, in predicting overall survival. The study underscores the comprehensive insight provided by ALRI, combining inflammatory, nutritional, and genetic information for robust prognostication in CRC patients. This user-friendly tool demonstrates promise for preoperative prognosis and personalized treatment strategies, emphasizing the crucial role of inflammation and nutrition in CRC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.